Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP380795.RAe-tP28KJIx4rLN7hRC4XojanIsz9hqKJp_LNNl7aYA0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP380795.RAe-tP28KJIx4rLN7hRC4XojanIsz9hqKJp_LNNl7aYA0130_assertion type Assertion NP380795.RAe-tP28KJIx4rLN7hRC4XojanIsz9hqKJp_LNNl7aYA0130_head.
- NP380795.RAe-tP28KJIx4rLN7hRC4XojanIsz9hqKJp_LNNl7aYA0130_assertion description "[However, gemcitabine, paclitaxel, or cisplatin treatment enhanced the Akt activation, heterodimer formation of EGFR with HER3, and secretion of amphiregulin, indicating that the presence of gemcitabine promoted the activity of targeted molecules including amphiregulin, Akt, and HER3 for pancreatic cancer therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380795.RAe-tP28KJIx4rLN7hRC4XojanIsz9hqKJp_LNNl7aYA0130_provenance.
- NP380795.RAe-tP28KJIx4rLN7hRC4XojanIsz9hqKJp_LNNl7aYA0130_assertion evidence source_evidence_literature NP380795.RAe-tP28KJIx4rLN7hRC4XojanIsz9hqKJp_LNNl7aYA0130_provenance.
- NP380795.RAe-tP28KJIx4rLN7hRC4XojanIsz9hqKJp_LNNl7aYA0130_assertion SIO_000772 20726858 NP380795.RAe-tP28KJIx4rLN7hRC4XojanIsz9hqKJp_LNNl7aYA0130_provenance.
- NP380795.RAe-tP28KJIx4rLN7hRC4XojanIsz9hqKJp_LNNl7aYA0130_assertion wasDerivedFrom befree-20150227 NP380795.RAe-tP28KJIx4rLN7hRC4XojanIsz9hqKJp_LNNl7aYA0130_provenance.
- NP380795.RAe-tP28KJIx4rLN7hRC4XojanIsz9hqKJp_LNNl7aYA0130_assertion wasGeneratedBy ECO_0000203 NP380795.RAe-tP28KJIx4rLN7hRC4XojanIsz9hqKJp_LNNl7aYA0130_provenance.